Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $12.20 Average PT from Brokerages

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have earned an average recommendation of “Moderate Buy” from the five analysts that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $12.20.

A number of analysts recently commented on INO shares. StockNews.com upgraded shares of Inovio Pharmaceuticals to a “sell” rating in a research note on Friday, March 21st. HC Wainwright reiterated a “neutral” rating and issued a $3.00 price target on shares of Inovio Pharmaceuticals in a research report on Wednesday, March 19th. JMP Securities reiterated a “market outperform” rating and set a $18.00 price target on shares of Inovio Pharmaceuticals in a research report on Friday, January 10th. Finally, Royal Bank of Canada cut their price objective on shares of Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating for the company in a research report on Wednesday, March 19th.

Inovio Pharmaceuticals Stock Down 1.7 %

INO opened at $1.73 on Wednesday. The company’s 50-day moving average price is $2.03 and its two-hundred day moving average price is $3.50. Inovio Pharmaceuticals has a twelve month low of $1.68 and a twelve month high of $14.75. The stock has a market cap of $45.15 million, a price-to-earnings ratio of -0.43 and a beta of 0.92.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Tuesday, March 18th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.18. The firm had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.03 million. As a group, sell-side analysts anticipate that Inovio Pharmaceuticals will post -4.23 earnings per share for the current year.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets increased its stake in Inovio Pharmaceuticals by 177.0% in the third quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 3,630 shares during the last quarter. Barclays PLC boosted its holdings in shares of Inovio Pharmaceuticals by 15.0% in the 4th quarter. Barclays PLC now owns 39,114 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 5,111 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Inovio Pharmaceuticals by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 628,505 shares of the biopharmaceutical company’s stock valued at $1,150,000 after purchasing an additional 6,874 shares during the last quarter. MetLife Investment Management LLC raised its holdings in shares of Inovio Pharmaceuticals by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock valued at $88,000 after buying an additional 8,546 shares in the last quarter. Finally, Northern Trust Corp lifted its position in Inovio Pharmaceuticals by 6.4% in the 4th quarter. Northern Trust Corp now owns 219,057 shares of the biopharmaceutical company’s stock worth $401,000 after buying an additional 13,269 shares during the last quarter. 26.79% of the stock is owned by hedge funds and other institutional investors.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.